Stay updated on Pembrolizumab & Enfortumab in Rare Kidney Cancers Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Enfortumab in Rare Kidney Cancers Clinical Trial page.

Latest updates to the Pembrolizumab & Enfortumab in Rare Kidney Cancers Clinical Trial page
- Check2 days agoChange DetectedThe site’s displayed study total increased from 610,756 to 611,771; its stated geographic coverage remained the same.SummaryDifference0.1%

- Check9 days agoChange DetectedThe homepage now reports 610,756 studies, up from 609,551, with locations across all 50 states and 226 countries and territories.SummaryDifference0.1%

- Check16 days agoChange DetectedThe site now reports 609,551 studies, up from 608,415, with locations across all 50 states and 226 countries and territories. The site revision advanced from v3.7.2 to v3.8.0.SummaryDifference0.3%

- Check23 days agoChange DetectedThe homepage adds an NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” terminology and updates the number of studies listed from 607,349 to 608,415.SummaryDifference1%

- Check30 days agoChange DetectedThe site now reports 607,349 studies, up from 606,601, across all 50 states and 226 countries and territories. The displayed site revision also advanced from v3.7.1 to v3.7.2.SummaryDifference0.4%

- Check37 days agoChange DetectedThe homepage now reports 606,601 studies across the listed locations, up from 605,599. The site revision is updated from v3.7.0 to v3.7.1.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Enfortumab in Rare Kidney Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Enfortumab in Rare Kidney Cancers Clinical Trial page.